



## miRagen Therapeutics to Report First Quarter 2019 Financial Results and Host a Conference Call on May 8<sup>th</sup>

Company Release – 4/25/2019 8:00 AM ET

BOULDER, CO, April 25, 2019 – miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will host a conference call on Wednesday, May 8th, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2019.

Participants may access the call by dialing 877-407-0789 in the U.S. or 201-689-8562 outside the U.S. and providing the conference ID number: 13689475. The call will also be webcast and can be accessed from the Investors and Media section of the Company's website at [www.miragen.com](http://www.miragen.com). A replay of this conference call will be available on miRagen's website approximately one hour after the event.

### About miRagen Therapeutics, Inc.

miRagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. miRagen has three clinical stage product candidates, cobomarsen, remlarsen, and MRG-110. miRagen's clinical product candidate for the treatment of certain cancers, cobomarsen, is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers, as well as certain cells involved in inflammation. miRagen's clinical product candidate for the treatment of pathological fibrosis, remlarsen, is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary and ocular fibrosis, as well as systemic sclerosis. MRG-110, an inhibitor of microRNA-92, is being developed under a license and collaboration agreement with Servier for the treatment of

heart failure and other ischemic disease. In addition to these programs, miRagen is developing a pipeline of preclinical product candidates. The goal of miRagen's translational medicine strategy is to progress rapidly to first-in-human studies once it has established the pharmacokinetics, pharmacodynamic, safety and manufacturability of the product candidate in preclinical studies. For more information, please visit [www.miragen.com](http://www.miragen.com).

For information on clinical trials please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov).

**Investor/Media Contact:**

Adam Levy  
Chief Business Officer  
(720) 407-4595  
[alevy@miragen.com](mailto:alevy@miragen.com)